AnaptysBio Q2 collaboration revenue doubles
I'm PortAI, I can summarize articles.
AnaptysBio reported a significant increase in Q2 collaboration revenue, more than doubling year-over-year. The net loss narrowed to $38.6 million from $46.7 million. The company repurchased 9.3% of its shares, indicating confidence in its financial position. Positive Phase 2b trial results for rosnilimab in rheumatoid arthritis were announced, and enrollment for a Phase 2 trial in ulcerative colitis was completed. Analysts maintain a "buy" rating, with a median 12-month price target of $45.50, reflecting a potential upside of 47.9% from its recent closing price.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments